# **Mississippi edicaid** Volume 6, Issue 3

### September 1999

## Bulletin

### Eligibility Verification through the Internet

### nside

this

### ssue

Change in Bilirubin Light/Blanket Fee<sup>2</sup>

Policy and Procedure for Medicaid Reimbursement for Synagis <sup>TM</sup> (palivizumab) in the Office Setting	2
Certificate of Medical Necessity Synagis <sup>TM</sup> (palivizumab) and/ or Respigam form	3
Y2K Status	4
HealthMACS City/ Zip Enrollment Process	4
HealthMACS Change in Age Assignment for Pediatricians	4
Pharmacy Permit Renewals for DME	5
Drug Utilization Review (DUR) Update	5
Checkwrite and	

ESC Cut-Off

Schedule

6

Medicaid providers that use MediFAX® as their eligibility verification vendor can now access MediFAX® databases using the Internet. The Internet address is <u>www.mediFAX.com</u>. A customer with a unique identification code can access the site using an IBM-compatible PC equipped with a Hayes-compatible modem and an Internet browser like Netscape or Microsoft's Internet Explorer. No additional software is needed.

The MediFAX<sup>®</sup> site is a secure connection and meets the HCFA criteria for encryption that is required to process transactions. Upon entering the site, the user selects the appropriate commercial or public payor database for the search. Basic data about the beneficiary is input using a fill in the blank form that each user receives specific to the selected database. Both individual and batch processing is available. Transactions can then be printed using the browser's print function.

Any authenticated provider may gain access to the MediFAX® database via the Internet using a PC with minimum requirements. Internet participants are greeted with a user-friendly interface.

Minimum requirements recommended by MediFAX® are a Pentium PC running Windows '95 with 16 megabytes of RAM and a 28.8 modem. A web browser that supports SSL version 3.0 or higher like Netscape® or Microsoft® Internet Explorer is also required.



#### Change in Bilirubin Light/Blanket Fee

The current DME Fee Schedule lists the daily rental allowance for HCPCS Code E0202 (Modifier 2) as \$1.67. This allowance is being changed to \$75.00 per day. DME Suppliers are reminded that this item must be precertified through HealthSystems of Mississippi.

### Policy and Procedure for Medicaid Reimbursement for Synagis<sup>™</sup> (palivizumab) in the Office Setting

SYNAGIS<sup>TM</sup> (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk for RSV disease. On November 1, 1998, the DOM began reimbursing physicians for SYNAGIS<sup>TM</sup> (palivizumab) injections using HCPCS code J3490 (Injection, palivizumab, per 1 mg IM). This drug will be reimbursed for the RSV season (November through April). Medicaid reimburses \$11.52/mg. Prior authorization is required and certain clinical criteria must be met (see below). All claims must be submitted with the diagnosis code V07.2 (Prophylactic immunotherapy) and an appropriate ancillary diagnosis (example BPD, lung/respiratory failure).

- Prior Authorization for Synagis<sup>TM</sup> (palivizumab) must be obtained using the Plan of Care (POC) Authorization Request form (MA-1148). The POC must be submitted to the EPSDT Unit of the Division of Medicaid (DOM) and processed by the DOM prior to administering Synagis<sup>TM</sup> (palivizumab) to any Medicaid eligible child. If an infant or child is hospitalized, the physician should initiate the prior authorization process before discharge from the hospital. The DOM will not authorize payment for services rendered without proper prior authorization.
- ✤ The Certificate of Medical Necessity (CMN) for Synagis<sup>TM</sup> (palivizumab), located on the next page, must be attached to the Plan of Care form. No substitute for the CMN form will be accepted.
- All potential Synagis<sup>TM</sup> (palivizumab) beneficiaries must meet criteria in one of the four (4) categories (see CMN Part II).
- All authorizations for Synagis<sup>™</sup> (palivizumab) will end at age two (last day of the child's birthday month).
- Authorization will be for the RSV season only (November through April).

If the drug is not supplied by the physician's office but is supplied by a pharmacy the same prior authorization limits and clinical criteria will apply. The pharmacist must have a valid, approved prior authorization before supplying the drug.

If you have any questions, please call Rosemary Beason at 601-359-6150.

SYNAGIS™ (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk for RSV disease.



### CERTIFICATE OF MEDICAL NECESSITY SYNAGIS<sup>TM</sup> (palivizumab) and/or Respigam

Actual Start Date for Treatment: (MM/DD/YY)       /         PART II         CRITERIA FOR SYNAGIS <sup>TM</sup> (palivizomab) and/or Respigam         Category 1       Category 2 $\Box$ prematurity of $\leq 35$ weeks gestation $\Box$ prematurity of $\leq 35$ weeks gestation $\bigcirc -2$ years old $\Box$ without bronchopulmonary dysplasia $\bigcirc$ oxygen therapy-current $\bigcirc -6$ months during RSV season only $\bigcirc$ oxygen therapy within past six months $\bigcirc -2$ years old $\square$ prematurity of $\leq 32$ weeks gestation $\bigcirc -2$ years old $\square$ origination of months-2 years old $\bigcirc -2$ years old $\square$ without bronchopulmonary dysplasia $\bigcirc -2$ years old $\square$ ovidence of at least one RSV risk factor $\bigcirc -2$ years old $\square$ without bronchopulmonary dysplasia $\square$ evidence of at least one RSV risk factor $\square$ certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by the Division of Medicaid. I will be supervising the patient's treatment. This is an initial certification.	PART I			
City:	Patient's Name:	DOB/SEX: Gestational Age		
MEDICATION         nitial Treatment: $\subseteq$ SYNAGIS <sup>TM</sup> RESPIGAM         ROUTE       Dose       Frequency         Date of Service:       Inpatient       Outpatient Hospital       Office         Place of Service       Inpatient       Outpatient Hospital       Office         Proposed Dates of Treatment:       (MM/YY) through (MM/YY)	Street Address	Current weight (in kg) kg.		
nitial Treatment: □ SYNAGIS <sup>TM</sup> □ RESPIGAM          ROUTE       Dose       Frequency         Place of Service:       Inpatient       Outpatient Hospital       Office         Date of Initial Treatment:       SYNAGIS <sup>TM</sup> RESPIGAM         ROUTE       Dose       Frequency         Date of Service:       Inpatient       Outpatient Hospital       Office         Date of Service       Inpatient       Outpatient Hospital       Office         Proposed Dates of Treatment:       (MM/YY)_/through (MM/YY)_/				
ROUTE				
Place of Service:       Inpatient       Outpatient Hospital       Office         Date of Initial Treatment:       SYNAGIS <sup>TM</sup> RESPIGAM         ROUTE       Dose       Frequency         Place of Service       Inpatient       Outpatient Hospital       Office         Proposed Dates of Treatment:       Outpatient Hospital       Office         Proposed Dates of Treatment:       (MM/YY)				
Date of Initial Treatment: (MM/DD/YY) Dubsequent Treatment: SYNAGIS <sup>TM</sup> RESPIGAM ROUTE Dose Frequency Place of Service Inpatient Outpatient Hospital Office Proposed Dates of Treatment: (MM/YY) through (MM/YY) Part II Category 1 prematurity of ≤ 35 weeks gestation prematurity of ≤ 35 weeks gestation bronchopulmonary dysplasia O-6 months during RSV season only oxygen therapy-current O-6 months during RSV season only oxygen therapy dysplasia O-6 months during RSV risk factor category 3 Category 4 prematurity of ≤ 32 weeks gestation 32-35 weeks gestation oxygen therapy dysplasia O-6 months during RSV season only oxygen therapy within past six months Category 3 Category 4 32-35 weeks gestation	ROUTEDose	Frequency		
ROUTE       Dose       Frequency         Place of Service       Inpatient       Outpatient Hospital       Office         Proposed Dates of Treatment: (MM/YY)_/_ through (MM/YY)_/	Place of Service: □ Inpatient □ Outpatient Date of Initial Treatment: (MM/DD/YY)	Hospital		
Place of Service ☐ Inpatient ☐ Outpatient Hospital ☐ Office Proposed Dates of Treatment: (MM/YY) through (MM/YY)/ must be between November through April Actual Start Date for Treatment: (MM/DD/YY) // PART I CRITERIA FOR SYNAGIS <sup>TM</sup> (palivizomab) and/or Respigam Category 1 CRITERIA FOR SYNAGIS <sup>TM</sup> (palivizomab) and/or Respigam Demonstry of ≤ 35 weeks gestation Do -2 years old Do -6 months during RSV season only Oxygen therapy-current Oxygen therapy within past six months Category 3 Category 4 Demonstry of ≤ 32 weeks gestation Demonstry of ≤ 35 weeks ge	Subsequent Treatment:	□ RESPIGAM		
Proposed Dates of Treatment: (MM/YY)_/_ through (MM/YY)/         must be between November through April         Actual Start Date for Treatment: (MM/DD/YY)/         PART II         Category 1         prematurity of $\leq$ 35 weeks gestation         prematurity of $\leq$ 35 weeks gestation         prematurity of $\leq$ 35 weeks gestation         bronchopulmonary dysplasia         oxygen therapy-current         oxygen therapy within past six months         Category 3         prematurity of $\leq$ 32 weeks gestation         oxygen therapy within past six months         Category 4         group rematurity of $\leq$ 32 weeks gestation         oxygen therapy within past six months         Category 4         oxygen therapy within past six factor         oxygen therapy within past six months         Category 3         oxygen therapy within past six factor	ROUTEDose	Frequency		
Actual Start Date for Treatment: (MM/DD/YY)       /         PART II         CRITERIA FOR SYNAGIS <sup>TM</sup> (palivizomab) and/or Respigam         Category 1       Category 2         prematurity of $\leq$ 35 weeks gestation       prematurity of $\leq$ 35 weeks gestation         0-2 years old       prematurity of $\leq$ 35 weeks gestation         bronchopulmonary dysplasia       0-6 months during RSV season only         oxygen therapy-current       32-35 weeks gestation         oxygen therapy within past six months       32-35 weeks gestation         category 3       Category 4         prematurity of $\leq$ 32 weeks gestation       0-2 years old         without bronchopulmonary dysplasia       evidence of at least one RSV risk factor         certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by the Division of Medicaid. I will be supervising the patient's treatment. This is an initial certification.	Place of Service  Inpatient  Outpatient Hospita	l 🗆 Office		
PART II         CRITERIA FOR SYNAGIS™ (palivizonab) and/or Respigam         Category 1       Category 2         □ prematurity of ≤ 35 weeks gestation       □ prematurity of ≤ 35 weeks gestation         □ 0-2 years old       □ prematurity of ≤ 35 weeks gestation         □ 0-2 years old       □ without bronchopulmonary dysplasia         □ bronchopulmonary dysplasia       □ 0-6 months during RSV season only         □ oxygen therapy within past six months       □ 32-35 weeks gestation         Category 4         □ prematurity of ≤ 32 weeks gestation       □ 32-35 weeks gestation         □ oxygen therapy within past six months       □ 0-2 years old         Category 4         □ prematurity of ≤ 32 weeks gestation       □ 0-2 years old         □ months-2 years old       □ 0-2 years old         □ without bronchopulmonary dysplasia       □ 0-2 years old         □ without bronchopulmonary dysplasia       □ evidence of at least one RSV risk factor         □ evidence of at least one RSV risk factor       □         □ certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by the Division of Medicaid. I will be supervising the patient's treatment. This is an initial certification.	Proposed Dates of Treatment: (MM/YY)_/_ through <i>must be between November through April</i>	(MM/YY)/		
CRITERIA FOR SYNAGIS™ (palivizomab) and/or Respigam         Category 1       Category 2         □ prematurity of ≤ 35 weeks gestation       □ prematurity of ≤ 35 weeks gestation         □ 0-2 years old       □ prematurity of ≤ 35 weeks gestation         □ bronchopulmonary dysplasia       □ 0-6 months during RSV season only         □ oxygen therapy-current       □ 32-35 weeks gestation         □ prematurity of ≤ 32 weeks gestation       □ 32-35 weeks gestation         □ months-2 years old       □ 0-2 years old         □ without bronchopulmonary dysplasia       □ 0-2 years old         □ prematurity of ≤ 32 weeks gestation       □ 32-35 weeks gestation         □ 0-2 years old       □ 0-2 years old         □ without bronchopulmonary dysplasia       □ evidence of at least one RSV risk factor	Actual Start Date for Treatment: (MM/DD/YY)	_//		
$\Box$ prematurity of $\leq 35$ weeks gestation $\Box$ prematurity of $\leq 35$ weeks gestation $\Box$ o-2 years old $\Box$ without bronchopulmonary dysplasia $\Box$ bronchopulmonary dysplasia $\Box$ o-6 months during RSV season only $\Box$ oxygen therapy-current $\Box$ oxygen therapy within past six months $\Box$ oxygen therapy within past six months $\Box$ ategory 4 $\Box$ prematurity of $\leq 32$ weeks gestation $\Box$ 32-35 weeks gestation $\Box$ on ths-2 years old $\Box$ 0-2 years old $\Box$ without bronchopulmonary dysplasia $\Box$ evidence of at least one RSV risk factor $\Box$ certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by the Division of Medicaid. I will be supervising the patient's treatment. This is an initial certification.				
0-2 years old       □ without bronchopulmonary dysplasia         □ bronchopulmonary dysplasia       □ 0-6 months during RSV season only         □ oxygen therapy-current       □ 0-6 months during RSV season only         □ oxygen therapy within past six months       □ 2 tegory 4         □ prematurity of ≤ 32 weeks gestation       □ 32-35 weeks gestation         □ 6 months-2 years old       □ 0-2 years old         □ without bronchopulmonary dysplasia       □ evidence of at least one RSV risk factor         □ certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by the Division of Medicaid. I will be supervising the patient's treatment. This is an initial certification.	<u>Category 1</u>	Category 2		
<ul> <li>□ bronchopulmonary dysplasia</li> <li>□ 0-6 months during RSV season only</li> <li>□ oxygen therapy-current</li> <li>□ oxygen therapy within past six months</li> <li>Category 3</li> <li>□ prematurity of ≤ 32 weeks gestation</li> <li>□ 32-35 weeks gestation</li> <li>□ 0-2 years old</li> <li>□ 0-2 years old</li> <li>□ evidence of at least one RSV risk factor</li> <li>Certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by the Division of Medicaid. I will be supervising the patient's treatment. This is an initial certification.</li> </ul>	$\Box$ prematurity of $\leq$ 35 weeks gestation			
$\Box$ oxygen therapy-current $\Box$ oxygen therapy within past six months $\Box$ ategory 3 $\Box$ prematurity of $\leq 32$ weeks gestation $\Box$ or $D = 32$ so that $\Box$ or $\Box$ or $D = 32$ so that $\Box$ or				
$\Box$ oxygen therapy within past six monthsCategory 3Category 4 $\Box$ prematurity of $\leq 32$ weeks gestation $\Box$ 32-35 weeks gestation $\Box$ 6 months-2 years old $\Box$ 0-2 years old $\Box$ without bronchopulmonary dysplasia $\Box$ evidence of at least one RSV risk factor $\Box$ certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by the Division of Medicaid. I will be supervising the patient's treatment. This is an initial certification.		$\Box$ 0-6 months during RSV season only		
□ prematurity of ≤ 32 weeks gestation       □ 32-35 weeks gestation         □ 6 months-2 years old       □ 0-2 years old         □ without bronchopulmonary dysplasia       □ evidence of at least one RSV risk factor         □ evidence of at least one RSV risk factor       □ evidence of at least one RSV risk factor         □ certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by the Division of Medicaid. I will be supervising the patient's treatment. This is an initial certification.	<ul> <li>oxygen therapy-current</li> <li>oxygen therapy within past six months</li> </ul>			
□ prematurity of ≤ 32 weeks gestation       □ 32-35 weeks gestation         □ 6 months-2 years old       □ 0-2 years old         □ without bronchopulmonary dysplasia       □ evidence of at least one RSV risk factor         □ evidence of at least one RSV risk factor       □ evidence of at least one RSV risk factor         □ certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by the Division of Medicaid. I will be supervising the patient's treatment. This is an initial certification.	Category 3	Category 4		
<ul> <li>without bronchopulmonary dysplasia</li> <li>evidence of at least one RSV risk factor</li> <li><i>certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by the Division of Medicaid. I will be supervising the patient's treatment. This is an initial certification.</i></li> </ul>	$\Box$ prematurity of $\leq 32$ weeks gestation	□ 32-35 weeks gestation		
<ul> <li>evidence of at least one RSV risk factor</li> <li>certify that this treatment is indicated and necessary and meets the guidelines for use as outlined by the Division of Medicaid. I will be supervising the patient's treatment. This is an initial certification.</li> </ul>	$\Box$ 6 months-2 years old			
Medicaid. I will be supervising the patient's treatment. This is an initial certification.	<ul> <li>without bronchopulmonary dysplasia</li> <li>evidence of at least one RSV risk factor</li> </ul>	$\Box$ evidence of at least one RSV risk factor		
Physician's Signature: Telephone#: ()				
	Physician's Signature:	Telephone#: ( )		
Physician's Name:(please print)	Physician's Name:(please print)			
City/State:Zip Code:	City/State:	Zip Code:		

Attach this certificate to the Plan of Care Authorization Request Form (MA-1148). OTHER Certificates of Medical Necessity will not be accepted.

### Y2K Status

Effective March 1999, the Division of Medicaid (DOM) moved all Y2K remediated code into the production environment and on June 28, 1999, began populating individual provider and beneficiary master file records with end dates within the new millennium. With these changes in place, the Medicaid Management Information System (MMIS) is now able to accept claims with dates of service after December 31, 1999, for testing with individual providers and third party billers.

Electronic test claims may be submitted using the standard test Bulletin Board System (BBS). Please refer to your provider manual for instructions. Electronic Data Interchange (EDI) operators are available weekdays from 9:00 AM to 5:00 PM at 1-800-884-3222 to help with instructions for the testing and transmission process.

Please read the Medicaid Provider Bulletins and RA Banner Messages, or visit the web page for the DOM at <u>www.dom.state.ms.us</u> for updates on the Y2K initiative.

### HealthMACS City/Zip Enrollment Process

Effective September 1, 1999, the maximum enrollees a HealthMACS primary care provider (PCP) participating in the monthly city/zip enrollment process may receive increases from 25 to 35 enrollees. The enrollment is based on the PCP and Medicaid beneficiary having an exact city/zip match, and the Medicaid beneficiary and/or family having no history with another PCP. This increase in city/zip enrollment is based on the results of the HealthMACS survey. Please see the June 1999 Medicaid Provider Bulletin article entitled "HealthMACS Survey Results" for survey results.

If you are a HealthMACS PCP and are interested in receiving more information about the city/zip enrollment process or if you have questions regarding the HealthMACS program, please contact the Managed Care Division at 601-359-6133 or 1-800-421-2408.

### HealthMACS Change in Age Assignment for Pediatricians

Beginning September 1999, HealthMACS primary care providers (PCP) with specialties in pediatrics will be assigned HealthMACS enrollees ages 0 to 18. In the past, pediatricians who participated in HealthMACS as PCPs had their assignments limited to enrollees ages 0 to 13. PCPs may begin seeing these children on their October enrollment report. This change is in response to replies received from the HealthMACS survey in which pediatric PCPs indicated that they wanted the age assignment increased to age 18. If you are a participating



HealthMACS pediatrician and are assigned children not in the desired age range you wish to see, please follow the procedures in Chapter 4: HealthMACS, Attachment F, PCP Request for Beneficiary PCP Enrollment Change, in the provider manual. To request assignment of children ages 18 to 21, call the toll-free Managed Care Hotline at 1-800-884-3240.

If you have questions regarding the HealthMACS program or wish to enroll as a participating HealthMACS PCP, please call 1-800-884-3240.

During the last eighteen months, the Medicaid Management Information System (MMIS) has undergone extensive Y2K remediation and testing.

Effective September 1, 1999, the maximum enrollees a HealthMACS primary care provider (PCP) participating in the monthly city/zip enrollment process may receive increases from 25 to 35 enrollees.

### **Pharmacy Permit Renewals for DME**

According to the Mississippi Board of Pharmacy regulations (Article XXXVIII, Section 1B), Durable Medical Equipment (DME) providers are required to obtain a permit renewal annually from the Board of Pharmacy. Upon renewal, providers must submit a copy of the permit to EDS to maintain participation in the Mississippi Medicaid Program. The provider participation end date coincides with the expiration date of the permit. If a copy of the permit is not forwarded to EDS by the expiration date, it may result in the closure of your Medicaid provider number.

### Drug Utilization Review (DUR) Update

Heritage Information Systems, Inc. (HIS) is the contractor for the Division of Medicaid's Retrospective Drug Utilization Review (DUR) Program. HIS's analysis of medical and pharmacy claims data provides the Division of Medicaid with information about drug utilization. One of the goals of this program is to help improve clinical outcomes in a cost-effective manner. Prescribers may receive letters containing patientspecific information that use certain terms that may be unfamiliar. Two terms commonly used are:

- PUPM: Per User Per Month. This is a term used to indicate the relative cost of various therapies. For example, a diuretic, such as HCTZ, may have relatively low PUPM cost, while a proton pump inhibitor, such as omeprazole or lansoprazole, will have a relatively high PUPM cost.
- Unique Patient: The number of patients who received a particular drug within a specified time. This term allows identification for patients without any duplication.

Several actual examples obtained from data analysis are provided below. The claims analysis period used for these illustrations was April 1998 through March 1999.

Examples
----------

Second Generation Sulfonylureas	Rank	PUPM cost
Glyburide	1	\$26.45
Glimepiride	2	\$19.89
Glipizide	3	\$16.61

Drug Class	Rank	Unique Patients*
NSAIDs	1	17,397
2 <sup>nd</sup> Generation Sulfonylureas	2	8,081
Atypical Antipsychotics	3	5,909

\*average number of unique patients per month

If you have questions about the use of these terms in correspondence that you receive, please call Clifton Osbon, R.PH., Clinical Manager at 601-362-3388 or 1-888-447-8707.

Pharmacy Permit Renewals for Durable Medical Equipment (DME) providers are required by the Mississippi Board of Pharmacy for continued operation as a DME provider.

#### Mississippi Medicaid Bulletin Bulk Rate U.S. Postage PAID EDS Jackson, MS 111 East Capitol, Suite 400 Permit No. 584 Jackson, MS 39201-2121 If you have any questions related to the topics in this bulletin, please contact the EDS Correspondence Unit at 1-800-884-3222 or 601-960-2800. Mississippi Medicaid Bulletins and Manuals are on the Web! www.dom.state.ms.us Contact EDS Publications if you would like to receive the Mississippi Medicaid Bulletin, or have an interest in what septern ber you would like to see. Fax EDS Publications at 601-960-2807, or e-mail publications@msxix.hcg.eds.com. EDS September 1999 <u>Monday</u> Wednesday <u>**T**hursday</u> **T**uesday Sunday **F**riday Saturday HealthMACS 2 3 Checkwrite/Checkwrite/Checkwrite/Checkwrite/Checkwri 4 changes see page 4. ESC Cut-Off 5 pm DOM & 5 7 10 8 9 11 6 EDS closed for Labor Day. ESC Cut-Off 5 pm 18 12 15 17 13 14 16 ESC Cut-Off 5 pm 22 20 21 25 19 23 24 ESC Cut-Off 5 pm 26 27 28 29 30

Checkwrites and Remittance Advices are dated every Monday. However, funds are not transferred until the following Thursday and Remittance Advices usually arrive the following Friday.

ESC Cut-Off 5 pm